Tesla Recalls Model...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NYSE)
$39.43 -0.21 | -0.53%
06/19/13 - 01:41 PM ET
Portfolios with TEVA
- Portfolio NameUser Type
- UserDonnie Portfolio 2 High Grade
- UserMain
- UserLong Term Stock Picks
- UserTRIG
- Userfun and games
- Userabangser Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
Latest TEVA Headlines from TheStreet
- 3 Stocks Dragging The Drugs Industry Downward 06.19.13 | 01:06 pm
- Cooper Tire Sells to Apollo Tyres
06.12.13 | 11:06 am - Cooper Tire Is Bought for $2.22 Billion: Ahead of the Ticker 06.12.13 | 10:06 am
- Teva Pharmaceutical Industries Ltd Stock Upgraded (TEVA) 06.11.13 | 10:06 am
- Teva Pharmaceutical Industries Ltd Stock Buy Recommendation Reiterated (TEVA) 06.11.13 | 10:06 am
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner 06.10.13 | 05:06 pm
- 5 Drugs Stocks On The Rise 06.10.13 | 01:06 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 06.03.13 | 10:06 am
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 05.21.13 | 10:05 am
- Ireland Welcomes Watson Pharmaceuticals, an American Success 05.20.13 | 02:05 pm
Press Releases for TEVA
- Teva Strengthens Respiratory Franchise With Acquisition Of MicroDose Therapeutx - Business Wire 06.17.13 | 09:06 am
- Teva Announces AZILECT® (Rasagiline Tablets) Data To Be Presented At The 2013 International Congress Of Parkinson’s Disease And Movement Disorders - Business Wire 06.14.13 | 08:06 am
- Alexza Announces Conference Call To Discuss Agreement With Teva To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Teva And Alexza Announce Teva's License To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- OncoGenex Announces Plans For The Initiation Of The Rainier⿢ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer - PR Newswire 05.01.13 | 06:05 am
- OncoGenex Announces That The Borealis-2â¿¢ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment - PR Newswire 04.30.13 | 08:04 am
- More Than Half Of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail To Adequately Prepare In Advance Of Peak Allergy Seasons - PR Newswire 04.23.13 | 08:04 am
- Apolo Anton Ohno And Teva Respiratory Announce Finalists In National EIB All Starsâ¿¢ Contest - PR Newswire 04.16.13 | 08:04 am
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
Partner Headlines for TEVA
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy - Benzinga 03.29.13 | 11:03 am
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- Biogen MS Drug Approved; No 'Black Box' Label - Investor's Business Daily 03.27.13 | 06:03 pm
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Valeant Earnings, Sales Top Estimates; Street Shrugs - Investor's Business Daily 02.28.13 | 05:02 pm
- 3 Industries Set To Profit From An Aging Population - Seeking Alpha 01.31.13 | 09:01 am
- Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates - Investor's Business Daily 01.23.13 | 06:01 pm
- Teva Pharmaceuticals - Food For Thought - Seeking Alpha 01.15.13 | 08:01 am
